Patients with gastroparesis often suffer with chronic gastrointestinal symptoms that are not adequately treated due to both a lack of understanding of the underlying pathophysiology and lack of effective treatments. The participation of Temple University in the NIH/NIDDK Gastroparesis Clinical Research Consortium and the proposed studies will help achieve the broad, long term objectives of improving the diagnosis and treatment of patients with gastroparesis. The PI and Temple University are exceptionally well qualified to continue to be one of the clinical centers in this consortium. Temple University has clinical expertise and an active research program in the evaluation and treatment of patients with gastroparesis.
The aims for this renewal of the Gastroparesis Consortium are threefold. First, to complete the ongoing and approved studies initiated by the GpCRC. These studies include NORIG: a randomized trial of nortriptyline vs. placebo for idiopathic gastroparesis;GLUMIT-DG: a pilot study of safety, feasibility and potential efficacy of continuous glucose monitoring and insulin pump therapy in diabetic gastroparesis;APRON: a randomized trial of aprepitant vs. placebo for the relief of nausea in patients with chronic nausea and vomiting of presumed gastric origin;PBG: pathological basis of gastroparesis, a tissue study from full thickness gastric biopsies. Second, to maintain and expand the Gastroparesis Registry.
Our aim i s to have at least four years of follow-up on patients and with up to nine years for some patients. This will require maintenance of the Registry and continued periodic follow-up visits over the next five years. In addition, we propose recruitment of new patients during continuation of the Gastroparesis Consortium with refinements to existing questionnaires and pathophysiologic measures, as well as new ones. This will allow us to answer questions related to the pathogenesis, severity grading, complications, treatment responses, and clinical outcomes in patients with gastroparesis. Third, to conduct new multicenter studies of gastroparesis investigating the etiology, pathogenesis, diagnosis, and treatment. The PI with his collaborators at Temple University propose a multicenter study aimed at improving the diagnosis of gastric motility disorders. The overall purpose of this project is to develop a single more comprehensive noninvasive test which evaluates several components of gastric motility and, thus, may improve the correlation between dyspeptic symptoms and gastric dysmotility. This will ultimately enable physicians to better target therapy to the underlying gastric pathophysiologic abnormality in patients with gastroparesis.

Public Health Relevance

Patients with gastroparesis often suffer with chronic gastrointestinal symptoms that are not adequately treated due to both a lack of understanding of the underlying causes and lack of effective treatments. The NIH Gastroparesis Clinical Research Consortium and the studies undertaken will help improve the understanding of gastroparesis and the diagnosis and treatment of patients with gastroparesis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01DK073975-06
Application #
8114478
Study Section
Special Emphasis Panel (ZDK1-GRB-8 (J2))
Program Officer
Hamilton, Frank A
Project Start
2006-04-15
Project End
2016-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
6
Fiscal Year
2011
Total Cost
$495,496
Indirect Cost
Name
Temple University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
057123192
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Parkman, Henry P; Yamada, Goro; Van Natta, Mark L et al. (2018) Ethnic, Racial, and Sex Differences in Etiology, Symptoms, Treatment, and Symptom Outcomes of Patients With Gastroparesis. Clin Gastroenterol Hepatol :
Hasler, W L; May, K P; Wilson, L A et al. (2018) Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. Neurogastroenterol Motil 30:
Parkman, H P; Hallinan, E K; Hasler, W L et al. (2017) Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. Neurogastroenterol Motil 29:
Grover, M; Bernard, C E; Pasricha, P J et al. (2017) Diabetic and idiopathic gastroparesis is associated with loss of CD206-positive macrophages in the gastric antrum. Neurogastroenterol Motil 29:
Camilleri, Michael; McCallum, Richard W; Tack, Jan et al. (2017) Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. Gastroenterology 153:1240-1250.e2
Koch, K L; Hasler, W L; Yates, K P et al. (2016) Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 vs type 2 diabetes. Neurogastroenterol Motil 28:1001-15
Parkman, H P; Hallinan, E K; Hasler, W L et al. (2016) Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. Neurogastroenterol Motil 28:1902-1914
Parkman, Henry P (2015) Idiopathic gastroparesis. Gastroenterol Clin North Am 44:59-68
Pasricha, Pankaj J; Yates, Katherine P; Nguyen, Linda et al. (2015) Outcomes and Factors Associated With Reduced Symptoms in Patients With Gastroparesis. Gastroenterology 149:1762-1774.e4
Bernard, C E; Gibbons, S J; Mann, I S et al. (2014) Association of low numbers of CD206-positive cells with loss of ICC in the gastric body of patients with diabetic gastroparesis. Neurogastroenterol Motil 26:1275-84

Showing the most recent 10 out of 27 publications